These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 12200685)
1. Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. Liu WM; Oakley PR; Joel SP Leukemia; 2002 Sep; 16(9):1705-12. PubMed ID: 12200685 [TBL] [Abstract][Full Text] [Related]
2. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486 [TBL] [Abstract][Full Text] [Related]
3. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166 [TBL] [Abstract][Full Text] [Related]
4. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific. Kissel CK; Schadendorf D; Röckmann H Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454 [TBL] [Abstract][Full Text] [Related]
5. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Jia L; Patwari Y; Srinivasula SM; Newland AC; Fernandes-Alnemri T; Alnemri ES; Kelsey SM Oncogene; 2001 Aug; 20(35):4817-26. PubMed ID: 11521193 [TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Giuliano M; Lauricella M; Vassallo E; Carabillò M; Vento R; Tesoriere G Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1300-11. PubMed ID: 9660477 [TBL] [Abstract][Full Text] [Related]
7. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Goldwasser F; Bae I; Fornace AJ; Pommier Y Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795 [TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins. Blood A; Edwards CJ; Ishii HH; Pat BK; Bryson G; Sculley TB; Gobe GC Arch Virol; 2004 Feb; 149(2):289-302. PubMed ID: 14745596 [TBL] [Abstract][Full Text] [Related]
9. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028 [TBL] [Abstract][Full Text] [Related]
10. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806 [TBL] [Abstract][Full Text] [Related]
11. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Ritke MK; Rusnak JM; Lazo JS; Allan WP; Dive C; Heer S; Yalowich JC Mol Pharmacol; 1994 Oct; 46(4):605-11. PubMed ID: 7969039 [TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase II inhibitors adriamycin and etoposide]. Meliksetian MB; Berezkina EV; Pavlenko MA; Grinchuk TM Tsitologiia; 1999; 41(7):615-21. PubMed ID: 10496023 [TBL] [Abstract][Full Text] [Related]
13. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Kaufmann SH Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800 [TBL] [Abstract][Full Text] [Related]
14. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700 [TBL] [Abstract][Full Text] [Related]
15. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins. Roy G; Horton JK; Roy R; Denning T; Mitra S; Boldogh I Oncogene; 2000 Jan; 19(1):141-50. PubMed ID: 10644989 [TBL] [Abstract][Full Text] [Related]
16. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Chen S; Gomez SP; McCarley D; Mainwaring MG Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828 [TBL] [Abstract][Full Text] [Related]
18. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Liu WM; Joel SP Cancer Chemother Pharmacol; 2003 Apr; 51(4):291-6. PubMed ID: 12721756 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Bowman KJ; Newell DR; Calvert AH; Curtin NJ Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322 [TBL] [Abstract][Full Text] [Related]
20. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]